{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:14:46Z","timestamp":1791440086032,"version":"4.3.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00210-025-04198-5","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T06:44:50Z","timestamp":1745995490000},"page":"14501-14513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of imeglimin, a novel oral agent in the management of type 2 diabetes mellitus: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"398","author":[{"given":"Jay","family":"Tewari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Ahmad","family":"Qidwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajoy","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anadika","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanshika","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineeta","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghda","family":"Mateen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabiha","family":"Khatoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafiul","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"4198_CR1","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s40262-023-01301-y","volume":"62","author":"C Chevalier","year":"2023","unstructured":"Chevalier C, Fouqueray P, Bolze S (2023) Imeglimin: a clinical pharmacology review. Clin Pharmacokinet 62:1393\u20131411. https:\/\/doi.org\/10.1007\/s40262-023-01301-y","journal-title":"Clin Pharmacokinet"},{"key":"4198_CR2","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2337\/dc20-0763","volume":"44","author":"J Dubourg","year":"2021","unstructured":"Dubourg J, Fouqueray P, Thang C et al (2021a) Efficacy and safety of imeglimin monotherapy versus placebo in japanese patients with type 2 diabetes (TIMES 1): a double-blind, randomized, placebo-controlled, parallel-group, multicenter phase 3 trial. Diabetes Care 44:952\u2013959. https:\/\/doi.org\/10.2337\/dc20-0763","journal-title":"Diabetes Care"},{"key":"4198_CR3","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/dom.14285","volume":"23","author":"J Dubourg","year":"2021","unstructured":"Dubourg J, Ueki K, Grouin J, Fouqueray P (2021b) Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial. Diabetes Obes Metab 23:800\u2013810. https:\/\/doi.org\/10.1111\/dom.14285","journal-title":"Diabetes Obes Metab"},{"key":"4198_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/dom.14613","volume":"24","author":"J Dubourg","year":"2022","unstructured":"Dubourg J, Fouqueray P, Quinslot D et al (2022) Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial. Diabetes, Obes Metab 24:609\u2013619. https:\/\/doi.org\/10.1111\/dom.14613","journal-title":"Diabetes, Obes Metab"},{"key":"4198_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2337\/dc12-0453","volume":"36","author":"P Fouqueray","year":"2013","unstructured":"Fouqueray P, Pirags V, Inzucchi SE et al (2013) The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 36:565\u2013568. https:\/\/doi.org\/10.2337\/dc12-0453","journal-title":"Diabetes Care"},{"key":"4198_CR6","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.2337\/dc13-2349","volume":"37","author":"P Fouqueray","year":"2014","unstructured":"Fouqueray P, Pirags V, Diamant M et al (2014) The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Diabetes Care 37:1924\u20131930. https:\/\/doi.org\/10.2337\/dc13-2349","journal-title":"Diabetes Care"},{"key":"4198_CR7","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.bja.2019.08.015","volume":"123","author":"A Granholm","year":"2019","unstructured":"Granholm A, Alhazzani W, M\u00f8ller MH (2019) Use of the GRADE approach in systematic reviews and guidelines. Br J Anaesth 123:554\u2013559. https:\/\/doi.org\/10.1016\/j.bja.2019.08.015","journal-title":"Br J Anaesth"},{"key":"4198_CR8","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA (2022) PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev 18:e1230. https:\/\/doi.org\/10.1002\/cl2.1230","journal-title":"Campbell Syst Rev"},{"key":"4198_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/dom.14277","volume":"23","author":"S Hallakou-Bozec","year":"2021","unstructured":"Hallakou-Bozec S, Vial G, Kergoat M et al (2021) Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab 23:664\u2013673. https:\/\/doi.org\/10.1111\/dom.14277","journal-title":"Diabetes Obes Metab"},{"key":"4198_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/DMSO.S495930","volume":"18","author":"A Itsukaichi","year":"2025","unstructured":"Itsukaichi A, Yoshikawa F, Fuchigami A et al (2025) Effect of imeglimin, a novel anti-diabetic agent, on insulin secretion and glycemic variability in type 2 diabetes treated with DPP-4 inhibitor: A 16-week, open label, pilot study. Diabetes Metab Syndr Obes 18:101\u2013111. https:\/\/doi.org\/10.2147\/DMSO.S495930","journal-title":"Diabetes Metab Syndr Obes"},{"key":"4198_CR11","doi-asserted-by":"publisher","unstructured":"Kaku K, Shimoda M, Osonoi T et al (2025) Efficacy and safety of imeglimin add\u2010on to DPP\u20104 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double\u2010blind FAMILIAR trial. Diabetes Obes Metab Online ahead of print. https:\/\/doi.org\/10.1111\/dom.16336","DOI":"10.1111\/dom.16336"},{"key":"4198_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111752","volume":"213","author":"H Katsuyama","year":"2024","unstructured":"Katsuyama H, Hakoshima M, Heshiki T et al (2024) Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in Japan. Diabetes Res Clin Pract 213:111752. https:\/\/doi.org\/10.1016\/j.diabres.2024.111752","journal-title":"Diabetes Res Clin Pract"},{"key":"4198_CR13","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s40265-021-01589-9","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN (2021) Imeglimin hydrochloride: first approval. Drugs 81:1683\u20131690. https:\/\/doi.org\/10.1007\/s40265-021-01589-9","journal-title":"Drugs"},{"key":"4198_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12:55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"4198_CR15","doi-asserted-by":"publisher","unstructured":"Nishikawa T, Higaki A, Kurokawa K et al (2025) Safety and Efficacy of Imeglimin for Type 2 Diabetes Mellitus in Patients With Heart Failure. In Vivo (Brooklyn) 39:375\u2013380. https:\/\/doi.org\/10.21873\/invivo.13838","DOI":"10.21873\/invivo.13838"},{"key":"4198_CR16","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s13300-022-01298-w","volume":"13","author":"T Oda","year":"2022","unstructured":"Oda T, Satoh M, Nagasawa K et al (2022) The effects of imeglimin on the daily glycemic profile evaluated by intermittently scanned continuous glucose monitoring: retrospective, single-center, observational study. Diabetes Ther 13:1635\u20131643. https:\/\/doi.org\/10.1007\/s13300-022-01298-w","journal-title":"Diabetes Ther"},{"key":"4198_CR17","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s13300-024-01639-x","volume":"15","author":"T Oyanagi","year":"2024","unstructured":"Oyanagi T, Kawanabe S, Tsukiyama H et al (2024) The effects of imeglimin on muscle strength in patients with type 2 diabetes: a prospective cohort study. Diabetes Ther 15:2323\u20132336. https:\/\/doi.org\/10.1007\/s13300-024-01639-x","journal-title":"Diabetes Ther"},{"key":"4198_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/dom.12452","volume":"17","author":"G Pacini","year":"2015","unstructured":"Pacini G, Mari A, Fouqueray P et al (2015) Imeglimin increases glucose-dependent insulin secretion and improves \u03b2-cell function in patients with type 2 diabetes. Diabetes Obes Metab 17:541\u2013545. https:\/\/doi.org\/10.1111\/dom.12452","journal-title":"Diabetes Obes Metab"},{"key":"4198_CR19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4198_CR20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.therap.2018.01.006","volume":"76","author":"C Piera-Mardemootoo","year":"2021","unstructured":"Piera-Mardemootoo C, Lambert P, Faillie J-L (2021) Efficacy of metformin on glycemic control and weight in drug-naive type 2 diabetes mellitus patients: A systematic review and meta-analysis of placebo-controlled randomized trials. Therapies 76:647\u2013656. https:\/\/doi.org\/10.1016\/j.therap.2018.01.006","journal-title":"Therapies"},{"key":"4198_CR21","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/j.1463-1326.2012.01611.x","volume":"14","author":"V Pirags","year":"2012","unstructured":"Pirags V, Lebovitz H, Fouqueray P (2012) Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab 14:852\u2013858. https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01611.x","journal-title":"Diabetes Obes Metab"},{"key":"4198_CR22","unstructured":"POXEL SA (2012) A dose-ranging, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of 4 doses of imeglimin after 24 weeks of treatment in subjects with type 2 diabetes mellitus. EudraCT Number 2012-004045-33 - Clinical trial results - EU Clinical Trials Register [Internet]. [cited 2024 Jul 13]. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-004045-33\/results"},{"key":"4198_CR23","unstructured":"R Core Team (2020) R: A language and environment for statistical computing, R Foundation for Statistical"},{"key":"4198_CR24","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/dom.14642","volume":"24","author":"C Reilhac","year":"2022","unstructured":"Reilhac C, Dubourg J, Thang C et al (2022) Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period. Diabetes Obes Metab 24:838\u2013848. https:\/\/doi.org\/10.1111\/dom.14642","journal-title":"Diabetes Obes Metab"},{"key":"4198_CR25","doi-asserted-by":"publisher","unstructured":"Saeedi P, Petersohn I, Salpea P et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 157:107843. https:\/\/doi.org\/10.1016\/j.diabres.2019.107843","DOI":"10.1016\/j.diabres.2019.107843"},{"key":"4198_CR26","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s13300-025-01693-z","volume":"16","author":"S Shaikh","year":"2025","unstructured":"Shaikh S, Sharma SK, Phatak S et al (2025) A multicenter, retrospective study to evaluate the effectiveness and safety of imeglimin in patients with type 2 diabetes mellitus in a real-world clinical setting (INDI-TIMES Study). Diabetes Ther 16:645\u2013661. https:\/\/doi.org\/10.1007\/s13300-025-01693-z","journal-title":"Diabetes Ther"},{"key":"4198_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11892-023-01531-1","volume":"24","author":"SC Shrestha","year":"2024","unstructured":"Shrestha SC, Gupta S (2024) Imeglimin: the New Kid on the Block. Curr Diab Rep 24:13\u201318. https:\/\/doi.org\/10.1007\/s11892-023-01531-1","journal-title":"Curr Diab Rep"},{"key":"4198_CR28","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"4198_CR29","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hr\u00f3bjartsson A, Kirkham J, J\u00fcni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Sch\u00fcnemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","DOI":"10.1136\/bmj.i4919"},{"key":"4198_CR30","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1111\/dom.16150","volume":"27","author":"A Takahashi","year":"2025","unstructured":"Takahashi A, Nomoto H, Yokoyama H et al (2025) Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: A multicenter, prospective, randomized, open-label, parallel-gro. Diabetes Obes Metab 27:1466\u20131476. https:\/\/doi.org\/10.1111\/dom.16150","journal-title":"Diabetes Obes Metab"},{"key":"4198_CR31","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1002\/edm2.371","volume":"5","author":"P Theurey","year":"2022","unstructured":"Theurey P, Thang C, Pirags V et al (2022) Phase 2 trial with imeglimin in patients with type 2 diabetes indicates effects on insulin secretion and sensitivity. Endocrinol Diabetes Metab 5:e371. https:\/\/doi.org\/10.1002\/edm2.371","journal-title":"Endocrinol Diabetes Metab"},{"key":"4198_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s13300-023-01370-z","volume":"14","author":"T Uchida","year":"2023","unstructured":"Uchida T, Ueno H, Konagata A et al (2023) Improving the effects of imeglimin on endothelial function: a prospective, single-center, observational study. Diabetes Ther 14:569\u2013579. https:\/\/doi.org\/10.1007\/s13300-023-01370-z","journal-title":"Diabetes Ther"},{"key":"4198_CR33","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/dom.16086","volume":"27","author":"R Usui","year":"2025","unstructured":"Usui R, Hamamoto Y, Imura M et al (2025) Differential effects of imeglimin and metformin on insulin and incretin secretion\u2014An exploratory randomized controlled trial. Diabetes Obes Metab 27:856\u2013865. https:\/\/doi.org\/10.1111\/dom.16086","journal-title":"Diabetes Obes Metab"},{"key":"4198_CR34","doi-asserted-by":"publisher","first-page":"e66322","DOI":"10.7759\/cureus.66322","volume":"16","author":"A Uto","year":"2024","unstructured":"Uto A, Ishinoda Y, Asaga T et al (2024) Imeglimin for type 2 diabetes mellitus: its efficacy and insight into the potential benefit for renal and liver function. Cureus 16:e66322. https:\/\/doi.org\/10.7759\/cureus.66322","journal-title":"Cureus"},{"key":"4198_CR35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11892-023-01521-3","volume":"23","author":"K Wnuk","year":"2023","unstructured":"Wnuk K, \u015awitalski J, Tatara T et al (2023) Workplace Interventions for type 2 diabetes mellitus prevention\u2014an umbrella review. Curr Diab Rep 23:293\u2013304. https:\/\/doi.org\/10.1007\/s11892-023-01521-3","journal-title":"Curr Diab Rep"},{"key":"4198_CR36","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3390\/biology12050726","volume":"12","author":"H Yanai","year":"2023","unstructured":"Yanai H, Adachi H, Hakoshima M, Katsuyama H (2023) Glucose-lowering effects of imeglimin and its possible beneficial effects on diabetic complications. Biology (Basel) 12:726. https:\/\/doi.org\/10.3390\/biology12050726","journal-title":"Biology (Basel)"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04198-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04198-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04198-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T04:13:56Z","timestamp":1759983236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04198-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["4198"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04198-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}